24 Aspirin is an effective anti-inflammatory and antiplatelet agent as an irreversible inhibitor of 25 cyclooxygenase. In 2016, the U.S. Preventive Services Task Force recommended aspirin for 26 primary prevention of cardiovascular disease (CVD) and colorectal cancer (CRC) in patients 27 aged 50 to 69 with a 10% or greater 10-year CVD risk. Due to the lack of literature describing 28 compliance with these recommendations in the uninsured patient population, we studied the 29 aspirin adherence for CVD and CRC prevention in several free medical clinics. We investigated 30 the records of 8857 uninsured patients who visited nine free medical clinics in the Tampa Bay 31 Area in 2016-2017. Aspirin compliance was assessed for patients with prior myocardial 32 infarction (MI) or coronary artery disease (CAD). 54% (n=1467) of patients met the criteria to 33 take aspirin for primary prevention of CVD and CRC, but just 17% of these patients aged 50-59 34 were on the medication. 16% percent of patients aged 60-69 were taking aspirin and significantly 35 more men than women were on aspirin (p=0.025). Of the 306 patients who had prior MI or CAD, 36 50% were on the medication for secondary prevention. Among the uninsured population, there is 37 low compliance with recommendations for aspirin usage to reduce the risk of CVD and CRC.
Introduction
43 Cardiovascular disease (CVD) is the leading cause of death in the United States according to 44 2016 data published in the National Vitals Statistics Report from the Centers for Disease Control 45 and Prevention [1] . As an irreversible inhibitor of cyclooxygenase, aspirin is widely prescribed 46 for CVD prevention due to its effectiveness as an anti-inflammatory and antiplatelet agent [2-
47 4]. Long-term use at low doses has additionally been associated with decreased risk of 48 colorectal cancer (CRC) [5] . In 2016, the U.S. Preventative Services Task Force (USPSTF) 49 recommended aspirin for primary prevention of CVD and CRC in patients aged 50 to 69 with a 50 10% or greater 10-year CVD risk. To determine the 10-year CVD risk, the USPSTF used a 51 calculator derived from the American College of Cardiology and American Heart Association 52 (ACC/AHA) pooled cohort equations. This is a class B recommendation for 50-59 year-olds and a 53 class C recommendation for 60-69 year-olds [6] . Class B recommendations indicate that "there 54 is high certainty that the net benefit is moderate or there is moderate certainty that the net 55 benefit is moderate to substantial", whereas Class C recommendations indicate "at least 56 moderate certainty that the benefit is small" and to offer the intervention to "selected patients 61 Currently, no studies have examined the use of aspirin in reducing the risk of CVD and CRC in 62 the uninsured population. One study found low rates of aspirin use for primary prevention in 74 recommendations for aspirin use in the primary and secondary prevention of CVD and risk 75 reduction for CRC among uninsured patients. Our secondary purpose was to assess inappropriate 76 aspirin use by uninsured patients who do not meet criteria for its usage.
78
Methods 79 We conducted a retrospective chart review that included 8857 uninsured patients who visited 80 nine free medical clinics in the Tampa Bay Area between January 1, 2016 and December 31, 81 2017. Age, sex, race, employment status, and history of MI, CAD, cerebrovascular accident, and 82 gastrointestinal ulcers were recorded. Cholesterol levels, blood pressure, diabetic status, and 83 smoking status were used to calculate 10-year Framingham risk scores [15] . The Framingham 84 risk score predicts the risk of developing hard coronary heart disease (myocardial infarction or 85 coronary death) within 10 years. Framingham scores, rather than the ACC/AHA pooled cohort 86 equations, were used to determine 10-year CAD risk because the patient information collected 87 through our chart review did not include all data points required by the pooled cohort equations.
88 The data for total cholesterol was not available, however low density lipoprotein cholesterol 89 levels were available. As a result, Framingham risk scores were more representative of the CVD 90 risk for our population of patients. 91 92 Ten-year Framingham risk scores for CAD were calculated for only the 50-69 year-old 93 population to determine which patients qualified to take aspirin for primary prevention of CVD 94 and CRC. Records of patients with a 10% or greater risk score were reviewed to determine if 95 they were taking aspirin for primary prevention of CVD and CRC, and records of patients with 96 prior MI or CAD were reviewed to determine if they were taking aspirin for secondary 97 prevention of CVD. 98 99 The secondary aim of this study was to evaluate inappropriate use of aspirin, which we defined 100 as patients taking aspirin with no history of MI, CAD, or cerebrovascular accident, having less 101 than a 10% 10-year Framingham risk score, or having gastrointestinal (GI) ulcers. Although 102 current guidelines from the AHA and American Stroke Association recommend aspirin for 103 patients with a history of ischemic stroke [16], increased risk of bleeding, including history of GI 104 ulcers, is a contraindication for aspirin usage [6] . Given the limited data set, our parameters 105 defining inappropriate aspirin use did not incorporate the various other factors that increase risk 106 of bleeding, such as bleeding disorders, severe liver disease, renal failure, and thrombocytopenia. 121 Of the 1467 patients who met the criteria to take aspirin for primary prevention of CVD and 122 CRC, 751 were aged 50-59 and 716 were aged 60-69. In the 50-59 year age group, 16.8% 123 (126/751) of the patients were taking aspirin, and sex, race, or employment status did not differ 124 between aspirin users and non-users. In the 60-69 year age group, 15.5% (111/716) were taking 125 aspirin (Fig. 2) , significantly more men than women were taking aspirin (p=0.025), and 126 Caucasians were more likely to be taking aspirin than patients of other races (p=0.011) ( 132 Of the 306 patients who met criteria to take aspirin for secondary prevention of CVD, 50% 133 (153/306) were taking aspirin. 55.2% (48/87) of patients who had a prior MI and 47.9% 134 (105/219) of patients who had a history of CAD were taking aspirin (Fig. 2) . The effects of sex 135 and race on compliance with aspirin recommendations were not statistically significant. Among 136 patients with a history of CAD, those who were currently employed were more likely to be 137 taking aspirin (p=0.04) ( Table 2) . 154 Previous studies reported underutilization of aspirin for the primary and secondary prevention of 155 CVD in the general population. One study reported 40.9% of patients were told by their 156 physician to take aspirin for primary prevention, with 79% complying. Comparably, 75.9% of 157 patients were told by their physician to take aspirin for secondary prevention, with 89.9% 158 complying [12] . Despite the seeming underuse of CVD risk score calculators, such as the 159 Framingham risk score calculator, providers may be considering the risk of GI bleeding and 160 hemorrhagic stroke associated with an aspirin regimen when evaluating patients. A low dose 161 aspirin regimen was found to increase the risk of GI bleeding by 58% and hemorrhagic stroke by 162 27% in patients using the medication for primary prevention of CVD [17] . Consideration of the 163 bleeding risks could play a role in the under-prescription of aspirin.
164
165 Within the general population, aspirin use is lower than that recommended by current guidelines.
166 Our results showed that uninsured patients had even lower rates of use than the general 167 population, indicating room to improve compliance to guidelines. These findings bring up the 168 question of why uninsured patients have suboptimal rates of aspirin use. Lack of health insurance 169 and a low socioeconomic status have been associated with medication non-adherence [18, 19] .
170 However, there is limited information regarding provider prescribing patterns in free medical 171 clinics. A combination of poor medication adherence and provider prescribing patterns could be 172 a possible explanation for the discrepancy between aspirin use among the uninsured and general 173 patient populations. 174 175 We also found inappropriate use of aspirin. Among patients in our study, 2.5% (172/6919) did 176 not meet guideline criteria but were taking aspirin. This result contrasts with that from a previous 177 study using a national database, which reported that 11.6% of patients were inappropriately 178 taking aspirin for primary prevention of CVD [20] . However, that study used older guideline 179 criteria that defined inappropriate aspirin use as an aspirin regimen in patients with a less than 180 6% 10-year risk of a CVD event. The 4% difference in guideline criteria could account for the 181 variance in frequency. The association between lack of health insurance and medication non-182 adherence could also contribute to the lower rate of inappropriate aspirin use among uninsured 183 patients compared to the general population. 
